



Does PGE₁ Vasodilator Prevent Orthopaedic Implant-Related Infection in Diabetes? Preliminary Results in a Mouse Model

Arianna B. Lovati^{1*}, Carlo L. Romanò², Lorenzo Monti², Christian Vassena³, Sara Previdi⁴, Lorenzo Drago^{3,5}

1 Cell and Tissue Engineering Laboratory, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy, **2** Dipartimento di Chirurgia Ricostruttiva e delle Infezioni Osteo-articolari, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy, **3** Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy, **4** Laboratory of Cancer Cachexia AIRC Start-Up, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, **5** Department of Biomedical Science for Health, University of Milan, Milan, Italy

Abstract

Background: Implant-related infections are characterized by bacterial colonization and biofilm formation on the prosthesis. Diabetes represents one of the risk factors that increase the chances of prosthetic infections because of related severe peripheral vascular disease. Vasodilatation can be a therapeutic option to overcome diabetic vascular damages and increase the local blood supply. In this study, the effect of a PGE₁ vasodilator on the incidence of surgical infections in diabetic mice was investigated.

Methodology: A *S. aureus* implant-related infection was induced in femurs of diabetic mice, then differently treated with a third generation cephalosporin alone or associated with a PGE₁ vasodilator. Variations in mouse body weight were evaluated as index of animal welfare. The femurs were harvested after 28 days and underwent both qualitative and quantitative analysis as micro-CT, histological and microbiological analyses.

Results: The analysis performed in this study demonstrated the increased host response to implant-related infection in diabetic mice treated with the combination of a PGE₁ and antibiotic. In this group, restrained signs of infections were identified by micro-CT and histological analysis. On the other hand, the diabetic mice treated with the antibiotic alone showed a severe infection and inability to successfully respond to the standard antimicrobial treatment.

Conclusions: The present study revealed interesting preliminary results in the use of a drug combination of antibiotic and vasodilator to prevent implant-related *Staphylococcus aureus* infections in a diabetic mouse model.

Citation: Lovati AB, Romanò CL, Monti L, Vassena C, Previdi S, et al. (2014) Does PGE₁ Vasodilator Prevent Orthopaedic Implant-Related Infection in Diabetes? Preliminary Results in a Mouse Model. *PLoS ONE* 9(4): e94758. doi:10.1371/journal.pone.0094758

Editor: Stephen Kates, University of Rochester, United States of America

Received: September 4, 2013; **Accepted:** March 19, 2014; **Published:** April 9, 2014

Copyright: © 2014 Lovati et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The entire work was funded by the Italian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: arianna.lovati@grupposandonato.it

Introduction

Implant-related infection has been recently reported as, respectively, the first and the third reason for failure of knee and hip prosthesis in the U.S. [1,2]. Infection rates after revision surgery are considerably higher (5–40%) than after primary replacement [3].

Implant-related infections represent the 65% of orthopaedic infections and they are characterized by bacterial colonization and biofilm formation on the prosthetic implant and within the contiguous tissues [4]. Bacteria within biofilm, in particular *Staphylococcus aureus*, are extremely resistant to antibiotics and persistent infections arise despite proper therapies [5]. Treatments usually involve debridement procedures, surgical revisions and long term antibiotic therapy. Nevertheless, some infections are not entirely eradicated and lead to implant failure or loss [6].

Patient co-morbidities - diabetes, obesity, immunodeficiency and vascular diseases - represent risk factors that increase the chances of implant-related infections. In particular, diabetes alters the tissue healing and induces a high susceptibility to infections with risk of mortality [7]. Diabetes results in several disorders such as peripheral neuropathy, vasculopathy and ischemia due to the compromised granulocyte adherence [8,9]. Neuropathy and angiopathy play a primary role in the development of infections in diabetic patients, in particular, the implant-site districts of these patients respond inadequately to pharmacological treatments [10,11]. Moreover, the decrease of blood supply increases tissue necrosis near the implant, reduces the healing process, and contributes to the development of osteomyelitis [12]. Frequently, these events lead to the implant loss and to revision surgeries with high costs. Thus, the reasons for failure of antibiotic treatments may be due to the severe peripheral vascular disease and

unsuccessful revascularization. In fact, the reduced peripheral blood flow in diabetics has been demonstrated to impede the systemic antibiotics to reach superficial wound and ulcers, thus limiting the effective control of continued tissue infection by bacteria [13]. A successful management of peri-prosthetic infections in diabetics is strictly based on their prevention and novel therapeutic approaches. The stimulation of local blood supply could be a therapeutic option to balance the vascular damages [14,15]. Prostaglandin E₁ (PGE₁) is a powerful vasodilator able to increase the peripheral blood perfusion by enhancing the endothelial function [16,17]. PGE₁ is already used for the treatment of chronic occlusive arterial disease [18] as either vasodilator or inhibitor of platelet aggregation [15,17,19,20]. PGE₁ plays a role to increase skin and muscle blood flow [21] as well as to generate new blood capillaries in ischemic skeletal muscles [22]. Moreover, the reduction of infections demonstrates the efficacy of PGE₁ in patients with prior irradiation after laryngeal surgeries [23]. Others demonstrated that the treatment of wounds with vasodilators in rats increased the local blood flow and antibiotic delivery to the site of injury [13]. Therefore, it is hypothesized that PGE₁ administration might decrease the incidence of surgical infections in diabetic patients. However, the role of PGE₁ in implant-related infections has not yet been evaluated.

In the present study, we investigated the effects of a PGE₁ on implant-related infections in a diabetic mouse model, as already described in our previous work [24]. To verify our hypothesis, we compared data obtained from mice treated with a cephalosporin or with the association of the cephalosporin and a PGE₁ vasodilator.

Materials and Methods

Ethics Statement

The Mario Negri Institute for Pharmacological Research (IRFMN) Animal Care and Use Committee (IACUC) approved the whole study (Permit N. 43_2013-B). Animals and their care were handled in compliance with institutional guidelines as defined in national (Law 116/92, Authorization n.19/2008-A issued March 6, 2008, by the Italian Ministry of Health) and international laws and policies (EEC Council Directive 86/609, OJ L 358. 1, December 12, 1987; Standards for the Care and Use of Laboratory Animals - UCLA, U. S. National Research Council, Statement of Compliance A5023-01, November 6, 1998). The animals were housed at the Institute's Animal Care Facilities that meet international standards; they were regularly checked by a certified veterinarian responsible for health monitoring, animal welfare supervision, experimental protocols and procedure revision.

Experimental design

The effects of the association of a PGE₁ vasodilator and a cephalosporin were tested on a previously validated diabetic mouse model of staphylococcal orthopaedic implant-related infection [24].

To this aim, NOD/ShiLtJ mice were assigned to one of three experimental groups (n = 8 animals in each group):

Group I Sham control (3 μ l PBS + Cephalosporin)

Group II Antibiotic treatment (*S. aureus* 10³ CFU/3 μ l + Cephalosporin)

Group III Combined treatment (*S. aureus* 10³ CFU/3 μ l + Cephalosporin + PGE₁ vasodilator)

Preparation of *S. aureus* for inoculation into the joint space

S. aureus strain ATCC 25923 was used in this study as described in our recent study [24]. Briefly, bacteria were cultured at 37°C overnight onto Mannitol Salt Agar (BioMerieux, France) and incubated into Brain Heart Infusion Broth (BioMerieux) at 37°C for 16 hours. The bacterial suspension was suspended in PBS to obtain a 0.5 McFarland turbidity (equal to about 1×10⁸ CFU/mL), then serially diluted with sterile saline solution and counts were performed to check for bacterial inoculum used for the experiments.

In vivo surgical procedures

Twenty-four female NOD/ShiLtJ type I diabetic 14 week old mice (mean body weight 23.3±1.3 g) (Jackson Laboratory) were used for this experiment. Blood glucose levels for diabetes were tested in the NOD/ShiLtJ mice directly by the provider before delivery. The mice were maintained under specific pathogen-free conditions and food was provided *ad libitum*. All procedures on the animals were performed under a laminar flow hood. The implantation of the intramedullary nail was performed as previously described [24,25] and maintained *in situ* for 28 days. A bacterial suspension of about 1×10³ CFU/mouse was injected in group II and III into the femoral canal after implantation according to the literature [25,26]. In the sham controls (group I), sterile PBS was injected as described above. Immediately after surgery, all animals received a one-shot injection of carprofen 5 mg/kg SC (Rimadyl, Pfizer, Italy) and ceftriaxone 60 mg/kg IM (Rocephin, Roche, Italy). The cephalosporin bactericidal effect on *S. aureus* strain ATCC 25923 was previously tested *in vitro*. Additionally, group III was treated intravenously with a PGE₁ vasodilator at a dosage of 10 μ g/kg (Prostavasin, Schwarz Pharma, Italy).

The animals were housed in separate cages for 24 h, then grouped four per cage, and daily clinically monitored. Pain was controlled with buprenorphine (0.1 mg/kg SC). After 4 weeks, the mice were euthanized by CO₂ inhalation to perform the investigations on the harvested samples.

Blood collection and analysis

To determine the total white blood cells (WBC) count, blood samples were collected from the animals' facial vein (n = 24) on day 0 and from the left ventricle immediately after sacrifice (day 28) as described by Lovati et al. 2013 [24]. EDTA anti-coagulated blood samples were used to obtain values of total WBC with an automatic cell counter for human use (Sysmex XT-1800, Dasit).

Micro-CT imaging and data analysis

To evaluate bone reaction, micro-CT analysis (n = 5 per group) were performed by two independent examiners on explanted femurs with an Explore Locus micro-CT scanner (GE Healthcare, London, Ontario, Canada), without using contrast agents. Protocols and procedures of micro-CT scan acquisitions were already described by Lovati et al. 2013 [24]. The images from each sample were binarized at identical thresholds to allow for unbiased identification of bone damage and osteolysis.

The image analysis was designed on a volume of interest (VOI) to evaluate the outer bone volume of the femur to measure any anatomical changes. Bone mineral density (BMD) was measured after calibration using a phantom placed in the field of view of the scanned specimens. The BMD (mg/cc) was measured on the bone volume designed on the femoral bone by the Micro View image

viewer (version 2.1.2; GE Healthcare). BMD data were then normalized on the baseline BMD obtained in the control group I.

Histological analysis

Femoral specimens ($n=4$ per group) were fixed in 10% formalin overnight, then decalcified in Mielodec (Bio-Optica, Milan, Italy), dehydrated, the metallic implants were removed, samples were embedded in paraffin, and cut into 5 μm sagittal sections. After deparaffinization, the slides were stained with Haematoxylin and Eosin (H&E) and Gram staining to assess the presence of bacteria, finally analyzed by three independent examiners using an Olympus IX71 light microscope. The inflammatory response and infection were both evaluated through the periosteal reaction, cortical bone and medullary canal changes according to the grading score (0 to 3) described in our previous study [24]. Briefly, the periosteum was analyzed for absence or presence of reaction; the cortex was mainly analyzed for absence or presence of polymorpho-nucleated cells, osteoclasts and bone resorption; and the medullary canal for absence or presence of polymorpho-nucleated cells and micro- and macroabscesses.

Microbiological analysis

To quantify bacteria within the explanted samples ($n=4$ per group), serial dilutions from sonicated fluids were plated onto Mueller-Hinton agar plates (Biomérieux, Marcy l'Etoile, France) and incubated for 16 h at 37°C. Briefly, sterile container containing explanted samples was filled with 1 ml of sterile saline and sonicated in an ultrasound bath (VWR, Milan, Italy) for 5 min with a frequency of 30 kHz and a power output of 300 W at room temperature. All samples were assayed by serial 10-fold dilution in sterile saline solution and then plated on solid growth medium. After incubation of the plates at 37°C for 16 h, colonies of Gram-positive catalase positive cocci, resembling those of *S. aureus*, were tested for coagulase activity with Coagulase Plasma (Remel Europe Ltd. Dartford, UK) and identified by means of API Staph assay (BioMérieux, Marcy l'Etoile, France). Positivity to catalase test consists in the development of gaseous oxygen when the colony was put in contact with oxygenated water. Coagulase test results positive when *S. aureus* colonies in contact with coagulase plasma, form a visible clot after incubation for 4–6 h at 37°C. Colonies identified as *S. aureus* grown on Mueller-Hinton agar plates were then counted. The detection limit (L. o. D) was ≤ 1.300 (Log CFU)/g of bone.

Statistical analysis

Comparisons between groups were analyzed with one-way analysis of variance (ANOVA) (Instat 2.0; Graphpad Software, San Diego, CA). Comparisons between groups and time points were analyzed with two-way ANOVA. When significant differences were detected, post hoc comparisons of means were performed using Bonferroni's procedure. Comparison between two groups was analyzed with unpaired t-test. All data are expressed as means \pm standard error (SEM). Values of $P < 0.05$ were considered statistically significant.

Results

Gross appearance and clinical data

The NOD/ShiLtJ mice displayed plasma glucose levels higher than 130 mg/dl at 14 weeks of age.

Groups I and III showed a slight lameness that solved within few days after implantation. On the contrary, most of the animals of group II, except one, developed subcutaneous swelling or abscesses and a marked lameness persist until the day of explantation. After

two weeks of implantation, one mouse of group II was euthanized because of the poor conditions and it was replaced by another animal. Four weeks after implantation, all mice were sacrificed and femurs were explanted. The gross appearance examination confirmed the clinical data reported above. Groups I and III did not show macroscopic signs of infection, while group II showed macroabscesses of the joint soft tissues and lymph node enlargement. Signs of infection in group II were related with a consistent loss of body weight by day 7 post-infection when compared with group I, which improved the body weight over time. The mice of group III showed a restricted body weight loss either at day 7 or at day 14 post-infection compared with group II. In group III, the body weight increased starting from day 14 and recovered better than group II at 28 days post-infection.

The histogram in Fig. 1 reports the percentage changes in body weight versus baseline (day of inoculation/implantation).

Blood analysis

After 28 days, no statistical difference was calculated among the experimental groups. A mild WBC increase was measured in group II (3.13%) compared to group I (1.96%) and group III (2.29%). In particular, no effects of the PGE₁ administration on the WBC count were detected in group III except a lower WBC decrease in group III compared with group II.

Micro-CT imaging analysis

Micro-CT fluoroscopic examination confirmed the correct placement of the intramedullary implant within the femoral canal in all the experimental groups (Fig. 2A).

The qualitative micro-CT analysis showed no damages in the cortical and endosteal bone either along the diaphysis or femoral condyles in groups I and III. In group II, the *S. aureus* infection established a diffuse bone loss of the femoral metaphysis and diaphysis associated with the disruption of the endosteal bone, the decrease of the cortical bone thickness and the enlargement of the femoral canal (Fig. 2B). The BMD analysis was performed on values of groups II and III normalized on the BMD mean of group I, as sham control. Group II displayed a statistically significant decrease in BMD compared with group III, as shown in the histogram of Fig. 2C.




Fig. 1. Relative changes in body weight. The histogram shows the relative changes in body weight in the experimental groups over time. A significant weight loss was measured in group II versus the control group I over time. Group III showed a significant body weight loss at day 14 after implantation compared to group I. Group III recovered body weight starting from the second week after surgery (two-way ANOVA, ** $P < 0.01$, * $P < 0.05$; $n = 8$). doi:10.1371/journal.pone.0094758.g001




Fig. 2. Representative micro-CT images and bone mineral density (BMD). A) Representative fluoroscopic image attests the correct placement of the implant within the femoral canal and the phantom calibration placed in the field of view; B) Magnified representative micro-CT images of the femurs containing metallic implants in transversal views in all the experimental groups. The images of groups I and III show an intact cortical bone profile of the whole femur. The image of group II shows a diffuse cortical and endosteal bone loss as signs of osteomyelitis; C) The histogram shows a high statistically significant difference in the BMD relative decrease of group II versus group III (unpaired t-test, *** $P < 0.0001$; $n = 5$).

doi:10.1371/journal.pone.0094758.g002

Histological analysis of bones and joints

Group I explants showed a normal aspect of the knee joint, absence of any signs of infection (Fig. 3A) and normal sized femoral canal (Fig. 3B). No bone resorption or periosteal reactions were present in these samples, the cortical bone of the diaphysis was unaffected and osteocytes appeared small with dense flattened nuclei (Fig. 3B small box). No bacteria were identified in Gram-positive staining (Fig. 3C).

In contrast, in group II, joint and bone were affected by moderate to severe inflammatory changes multifocally extending to surrounding soft tissues (muscles, tendons and ligaments). Severe chronic neutrophilic osteomyelitis and arthrosynovitis were found with multifocal abscesses and pyogranulomas with intralesional bacteria (Fig. 3D). Marked bone resorption of cortical bone and periosteal reaction were present together with irregularities of the bone surface facing the bone marrow cavity and presence of osteoclasts in the endosteal side (Fig. 3E). Numerous intralesional aggregates of Gram-positive bacteria (cocci) were detected in the medullary canal as well as in the joint space and within the muscle fibers (Fig. 3F).

In group III, a partially irregular surface of the articular cartilage of the knee joint was detected together with mild inflammatory changes of bone and joint when compared to group II (Fig. 3G). Diaphysis cortical bone was irregularly thickened and had moderate to marked signs of bone remodeling (cement lines,

new bone deposition) and overall appeared less dense with multifocal blood vessels, areas of woven bone and larger osteocytes compared to unaffected cortical bone of group I (Fig. 3H). Overall, dispersed Gram-positive bacteria were present in a smaller amount compared to group II (Fig. 3I).

The histological grading score showed a higher significant difference in group I compared to group II for all the analyzed regions, and a significant difference was identified in the medullary canal of group I compared to group III, as reported in the histogram of Fig. 4.

Microbiological analysis

After sonication, no bacterial growth was observed in group I (≤ 1.3 Log CFU/g bone). By contrast, great amounts of *S. aureus* bacteria were recovered in the samples of group II with a mean of 5.3 ± 1.2 (Log CFU)/g bone. A restricted amount of bacteria was also measured in the samples of group III with a mean of 3.6 ± 0.9 (Log CFU)/g bone. The histogram in Fig. 5 compares bacterial counts in all the experimental groups. A statistical difference was calculated between either group II or III compared with group I. Despite no statistically differences appeared between group II and III, the bacterial growth was lower in group III that received the association of antibiotic and vasodilator.




Fig. 3. Histology of the femurs in the experimental groups (n=4). Figures represent H&E staining in the left and middle panels and Gram-positive staining in the right panel. Legend: femur (F), tibia (T), cortical bone (CB), and medullary canal (MC). Group I - A) Normal aspect of the knee joint and absence of signs of infection (Magnification 2X, scale bar 1 mm); B) Absence of inflammatory cells in the medullary canal, of bone resorption or periosteal reaction (Magnification 4X, scale bar 0.5 mm) and presence of osteocytes within cortical bone lacunae (small box, Magnification 1000X); C) Absence of Gram-positive bacteria aggregates (Magnification 10X, scale bar 0.2 mm). Group II - D) Abscesses in the knee joint (black arrow) and in the medullary canal (Magnification 2X, scale bar 1 mm); E) Endosteal bone resorption (#), active osteoclasts (black arrows), marked periosteal reaction (*) (Magnification 4X, scale bar 0.5 mm) and diffuse enlargement of the medullary canal with osteoclastic resorption in the endosteal side (small box, Magnification 20X, scale bar 0.1 mm); F) Presence of numerous Gram-positive bacteria aggregates (Magnification 10X, scale bar 0.2 mm; small box, Magnification 1000X). Group III - G) Irregular surface of the articular cartilage of the knee joint and mild inflammatory changes of bone and joint (Magnification 2X, scale bar 1 mm); H) Diffuse increase of the vascular network and bone vessel enlargement (#) and areas of bone remodeling (black arrow) (Magnification 4X, scale bar 0.5 mm); large osteocytes embedded in cortical bone lacunae (small box, Magnification 1000X); I) Mild presence of dispersed Gram-positive bacteria within the medullary canal (Magnification 10X, scale bar 0.1 mm; small box, Magnification 1000X). doi:10.1371/journal.pone.0094758.g003




Fig. 4. Histological grading score histogram. The histogram shows a high statistically significant difference in the histological grading score in periosteum, cortex and medullary canal of group I versus group II and a difference in the score of the medullary canal of group I versus group III (two-way ANOVA, ***P<0.001; *P<0.05; n=4). doi:10.1371/journal.pone.0094758.g004

Discussion

In diabetic patients, the peripheral blood supply is impaired due to various degree of angiopathy and microvascular dysfunction [27]. The reduced tissue perfusion may compromise the delivery of drugs, in particular, in the lower limbs [28,29]. This impaired vascularization delays the tissue healing after surgery and increases the rate of implant-related infection despite aggressive antibiotic therapies [30]. Thus, the priority is to control the risk of infection by increasing both the vascular supply and the efficacy of antibiotics.

In this study, we found that the combination of a third generation cephalosporin with a PGE₁ vasodilator improved the host response to the implant-related *S. aureus* infection in the diabetic mouse model, the latter already described in our previous study [24]. Many studies described the properties of PGE₁ to maintain the blood perfusion, increase angiogenesis and inhibit platelet aggregation [16,31,32,33]. On this basis, we hypothesized




Fig. 5. Bacterial load in bones of all the experimental groups. No colonies were detected in group I, the sham control (L.o.D. = limit of detection). With an infecting dose of 1×10^3 CFU/mouse, a mean of 5.3 ± 1.2 (Log CFU)/g of bone was found in the explants of group II, with a statistical difference in respect to group I. A mean of 3.6 ± 0.9 (Log CFU)/g of bone was found in the explants of group III, with a statistical difference in respect to group I (one-way ANOVA, * $P < 0.05$; ** $P < 0.01$; $n = 4$).

doi:10.1371/journal.pone.0094758.g005

that the administration of a PGE₁ might enhance the antibiotic delivery in the lower extremities and decrease the bacterial colonization of the infected site. In the present study, the intravenous administration of PGE₁ has been chosen to avoid any potential systemic side effects as also suggested by others [22].

The change in body weight is an index of animal welfare, correlates with behavior in feeding and presence/absence of diseases [34]. The high statistical difference between group I and group II assesses the poor condition of the group II treated with the antibiotic alone, which showed an abnormal behavior in food intake. Differently, group III, treated with the association of the antibiotic and vasodilator, was able to regain body weight quicker and better respect to group II, and it showed no differences when compared to group I after 28 days from surgery. As reported elsewhere in diabetic patients, both the impaired bactericidal activity of polymorphonuclear cells [35–38] and the delayed hypersensitivity reaction of T-cell function [39,40] explain the poor response to infection of group II, which showed a very low body weight increase over time. Differently, in group III, the quick body weight regain might be related to the efficacy of PGE₁ in promoting the T-cell proliferation and oxygenation, as well as the response to infection and inflammation, as demonstrated also by others [41,42]. Furthermore, PGE₁ vasodilators have a direct cytoprotective effect by suppressing the production of proinflammatory cytokines [43,44], thus PGE₁ indirectly attenuate the cytotoxic effects of inflammation and improve the host defense [45]. To strongly support the PGE₁ modulatory effect on inflammation, the serum concentration of proinflammatory cytokines should be investigated (e.g. C reactive protein). Our study lacks of this analysis because of the not correctly established values in mouse serum [24,46].

Despite no statistical difference exists in WBC count among groups, the relative increase in total WBC count was lower in group III respect to group II. An increase in WBC count was expected because PGE₁ commonly inhibits the activation and adhesion of polymorphonuclear neutrophils. However, PGE₁ suppresses the release of proinflammatory cytokines from activated mononuclear cells, cytokines that can cause neutrophilia as demonstrated in animals [47] and humans [48]. PGE₁ has also an inhibitory effect on granulocyte proliferation [49] and may be the explanation for our observation.

Ischemia and poor blood supply enhance the bone susceptibility to microbial invasion. As the infection reaches the medullary canal, the pressure increases and causes the bacterial extension into the cortex by bone canals widening into the periosteum and adjacent soft tissues [50]. In our study, micro-CT detected clear changes within the cortical bone due to the infection in group II, confirming the development of a chronic osteomyelitis. In contrast, group III showed no signs of osteomyelitis and a lower decrease in BMD compared to group II. These data support the efficacy of the PGE₁ treatment to limit the bacterial extension within the bone tissue. Moreover, the higher BMD values in group III confirm the PGE₁-mediated anabolic osteogenic response and bone remodeling, as also demonstrated in other studies [51,52,53].

Histology confirmed the micro-CT results showing evident signs of infection in group II as compared to the other groups. In particular, endosteal and intracortical resorption by osteoclasts, inflammatory cell infiltration, periosteal reaction and bacteria in the site of implantation in group II were present, as typical signs of infection as also described in different species by others [38,54,55]. Differently, both in group I and III no or mild signs of chronic osteomyelitis were detected, respectively, together with normal sized medullary canal and the presence of active osteoblasts. Moreover, the increased cortical porosity and the bone remodeling in group III supported the hypothesis that PGE₁ stimulates bone anabolism and subperiosteal bone formation thanks to osteoblast recruitment, as also described by others [51,56,57]. These observations are also consistent with observations following a single systemic administration of PGE₁ in rats over a 4-week period [58,59] and dogs [60]. In further studies, specific evaluations of vascular network could be useful to confirm the angiogenic and vasodilation effect of PGE₁ on bone.

The microbiological analyses demonstrated a marked bacterial colonization in group II and a lower presence of bacteria in group III, despite no significant difference exists. It has been described that platelet aggregation together with fibrin and blood clots embeds bacteria at the site of infection withstanding the shear forces of blood flow [61]. The small difference between group II and group III with a clear decrease of bacterial count in group III can be explained by the antiplatelet activity of PGE₁ that reduces the platelet entrapping of bacteria, thus the resistance of staphylococcal biofilm to antibiotic, as also demonstrated by others [61,62]. This phenomenon is also supported by the histological results where the Gram positive staining highlighted a mild presence of dispersed bacteria within the medullary canal of group III, differently from bacterial clusters detected in group II. This effect, together with the increase of peripheral blood flow, contributes to a better host response to infection.

This study is effectively a single-dose study and the results are limited to this condition. Further evaluations with a larger group of animals are also necessary to investigate the immune system mechanisms, signaling pathways and the vascular changes as well as different PGE₁ dosages and systemic implications. However, the present study provides some interesting observations that prove the positive effects of the synergic PGE₁-antibiotic treatment on implant-related *S. aureus* orthopedic infections in diabetic mice.

Conclusions

In conclusion, we have successfully visualized and quantified bacterial colonization in diabetic mice treated with the association of a cephalosporin and a PGE₁ vasodilator. We were able to investigate the infectious processes throughout the course of the disease in the chronic phases comparing with an untreated sham control and with animals treated with a standard antibiotic

therapy. To our knowledge, this is the first study describing the use of PGE₁ as prophylaxis of the osteomyelitis and bacterial aggregation in diabetic implant-related bacterial infections. This novel approach, employing a validated diabetic animal model, can be used to examine in depth the signaling pathways and mechanisms activated by vasodilators to prevent osteomyelitis and to evaluate innovative therapeutic strategies for human use.

Acknowledgments

The authors also thank L. Nicola and E. De Vecchi, Laboratory of Clinical Chemistry and Microbiology (IRCCS Galeazzi Orthopaedic Institute), for

their technical assistance in carrying out the biochemical and microbiological assays.

Author Contributions

Conceived and designed the experiments: ABL CLR LM. Performed the experiments: ABL LM CV SP. Analyzed the data: ABL CV SP. Contributed reagents/materials/analysis tools: CLR. Wrote the paper: ABL CLR LD.

References

- Bozic KJ, Kurtz SM, Lau E, Ong K, Chiu V, et al. (2010) The Epidemiology of Revision Total Knee Arthroplasty in the United States. *Clin Orthop Relat Res* 468(1): 45–51.
- Ong KL, Kurtz SM, Lau E, Bozic KJ, Berry DJ, et al. (2009) Prosthetic joint infection risk after total hip arthroplasty in the Medicare population. *J Arthroplasty* 24(6): 105–109.
- Widmer AF (2001) New developments in diagnosis and treatment of infection in orthopedic implants. *Clin Infect Dis* 33 (Suppl 2): 94–106.
- Trampuz A, Osmon DR, Hanssen AD, Steckelberg JM, Patel R (2003) Molecular and antibiofilm approaches to prosthetic joint infection. *Clin Orthop* 414: 69–88.
- Fulkerson E, Valle CJ, Wise B, Walsh M, Preston C, et al. (2006) Antibiotic susceptibility of bacteria infecting total joint arthroplasty sites. *J Bone Joint Surg Am* 88: 1231–1237.
- Romanò CL, Romanò D, Logoluso N, Meani E (2010) Septic versus aseptic hip revision: how different? *J Orthop Traumatol* 11(3): 167–174.
- Bertoni AG, Saydah S, Brancati FL (2001) Diabetes and the risk of infection-related mortality in the U.S.. *Diabetes Care* 24(6): 1044–1049.
- Goodson WH III, Hung TK (1977) Studies of wound healing in experimental diabetes mellitus. *J Surg Res* 22: 221–227.
- Bagdade JD, Stewart M, Walters E (1978) Impaired granulocyte adherence. A reversible defect in host defense in patients with poorly controlled diabetes. *Diabetes* 27: 677–681.
- Lipsky BA (2007) Diabetic Foot Infections: Microbiology Made Modern? Array of hope. *Diabetes Care* 30(8): 2171–2172
- Eneroth M, Larsson J, Apelqvist J (1999) Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. *J Diabetes Complications* 13: 254–263.
- Lipsky BA (1997) Osteomyelitis of the Foot in Diabetic Patients. *Clinical Infectious Diseases* 25: 1318–1326.
- Cross SE, Thompson MJ, Roberts MS (1996) Distribution of systemically administered ampicillin, benzylpenicillin, and flucloxacillin in excisional wounds in diabetic and normal rats and effects of local topical vasodilator treatment. *Antimicrobial agents and chemotherapy* 40(7): 1703–1710.
- Isner JM, Asahara T (1999) Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. *J Clin Invest* 103: 1231–1236.
- Clover AJ, McCarthy MJ (2003) Developing strategies for therapeutic angiogenesis: vascular endothelial growth factor alone may not be the answer. *Br J Plast Surg* 56: 314.
- Makino H, Aoki M, Hashiya N, Yamasaki K, Hiraoka K, et al. (2004) Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor. *Hypertens Res* 27: 85–91.
- Mehrabi MR, Ekmekcioglu C, Stanek B, Thalhammer T, Tramaddon F, et al. (2001) Angiogenesis stimulation in explanted hearts from patients pre-treated with intravenous prostaglandin E (1). *J Heart Lung Transplant* 20: 465–473.
- Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H (1994) Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. *Circulation* 90: 818–822.
- Creutzig A, Caspary L (1991) Prostanoids in therapy of peripheral arterial occlusive disease. *Therapie* 46: 241–245.
- Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, et al. (2000) Coadministration of Angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. *Arterioscl Thromb Vasc Biol* 20: 2573–2578.
- Pasch AR, Ricotta JJ, Burke AR, O'Mara RE, DeWeese JA, et al. (1984) Effect of prostaglandin E1 on blood flow in normal and ischemic canine hind limbs. *Surgery* 95: 724–729.
- Moreschi D Jr, Fagundes DJ, Bersani Amado LE, Hernandez L, Moreschi HK (2007) Effects of prostaglandin E1(PGE1) in the genesis of blood capillaries in rat ischemic skeletal muscle: histological study. *J Vasc Bras* 6 (4): 316–324.
- Shiga K, Tateda M, Saijo S (2002) Complication-free laryngeal surgery after irradiation failure with prostaglandin E1 administration. *Ann Otol Rhinol Laryngol* 111: 783–788.
- Lovati AB, Drago L, Monti L, De Vecchi E, Previti S, et al. (2013) Diabetic mouse model of orthopaedic implant-related *Staphylococcus Aureus* infection. *PLoS ONE*: doi:10.1371/journal.pone.0067628
- Bernthal NM, Stavakis AI, Billi F, Cho JS, Kremen TJ, et al. (2010) A Mouse Model of Post-Arthroplasty *Staphylococcus aureus* Joint Infection to Evaluate In Vivo the Efficacy of Antimicrobial Implant Coatings. *PLoS ONE* 5(9): e12580: doi:10.1371/journal.pone.0012580.
- Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. *J Microbiol. Methods* 40: 175–179.
- Silvestre JS, Lévy BI (2006) Molecular basis of angiopathy in diabetes mellitus. *Circ Res* 98: 4–6.
- King GL, Brownlee M (1996) The cellular and molecular mechanisms of diabetic complications. *Endocrinol Metab Clin North Am* 25: 255–270.
- Faries PL, Teodorescu VJ, Morrissey NJ, Hollier LH, Marin ML (2004) The role of surgical revascularization in the management of diabetic foot wounds. *The American Journal of Surgery* 187: 34S–37S.
- Akbari CM, LoGerfo FW (1999) Diabetes and peripheral vascular disease. *J Vasc Surg* 30: 373–384.
- Kuss M, Heidrich H, Koettgen E (2003) Hemostatic and fibrinolytic effects of systemic prostaglandin E1 therapy in patients with peripheral arterial disease. *Vasa* 32: 145–148.
- Mehrabi MR, Serbecic N, Tamaddon F, Pacher R, Horvath R, et al. (2003) Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: Stimulation of therapeutic angiogenesis in vital and infarcted myocardium. *Biomed Pharmacother* 57: 173–178.
- Simons M (2005) Angiogenesis: where do we stand now? *Circulation* 111: 1556–1566.
- van Heeckeren AM, Tscheikuna J, Walenga RW, Konstan MW, Davis PB, et al. (2000) Effect of *Pseudomonas* infection on weight loss, lung mechanics, and cytokines in mice. *Am J Respir Crit Care Med* 161(1):271–9.
- Repine JE, Clawson CC, Goetz FC (1980) Bactericidal function of neutrophils from patients with acute bacterial infections and from diabetics. *J Infect Dis* 142: 869–875.
- Tater D, Tepaut B, Bercovici JP, Youinou P (1987) Polymorphonuclear cell derangements in type I diabetes. *Horm Metab Res* 19: 642–647.
- Marhoffer W, Stein M, Schleinkofer L, Federlin K (1993) Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus. *Diabetes Res Clin Pract* 19: 183–188.
- Rich J, Lee JC (2005) The Pathogenesis of *Staphylococcus aureus* Infection in the Diabetic NOD Mouse. *Diabetes* 54: 2904–2910.
- Spatz M, Eibl N, Hink S, Wolf HM, Fischer GF, et al. (2003) Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. *Cell Immunol* 221: 15–26.
- Rubinstein R, Genaro AM, Motta A, Cremaschi G, Wald MR (2008) Impaired immune responses in streptozotocin-induced type I diabetes in mice. Involvement of high glucose. *Clin Exp Immunol* 154: 235–246.
- Dooper MMBW, Wassink L, M'Rabet L, Graus YMF (2002) The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype. *Immunology* 107: 152–159.
- Gee MH, Tahamont MV, Flynn JT, Cox JW, Pullen RH, et al. (1987) Prostaglandin E1 prevents increased lung microvascular permeability during intravascular complement activation in sheep. *Circ Res* 61: 420–428.
- Widomski D, Fretland DJ, Gasielki AF, Collins PW (1997) The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. *Immunopharmacol Immunotoxicol* 19: 165–174.
- Ishikawa O, Kubota Y, Miyachi Y (1998) Prostaglandin E1 suppresses tumor necrosis factor-alpha and interleukin-10 production by lipopolysaccharides-stimulated mononuclear cells. *Eur J Pharmacol* 344: 95–98.
- Farrokhnia F, Makarem J, Mahmoodzadeh H, Andalib N (2012) Does perioperative prostaglandin E1 affect survival of patients with esophageal cancer? *World J Gastrointest Surg* 4(12): 284–288.

46. Teupser D, Weber O, Ro TN, Sass K, Thiery J, et al. (2011) No reduction of atherosclerosis in C - reactive protein (CRP)-deficient mice. *J Biological Chemistry* 286 (8): 6272–6279.
47. Ulich TR, del Castillo J, Keys M, Granger GA, Ni RX (1987) Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor- α -induced changes in circulating numbers of neutrophils and lymphocytes. *J Immunol* 139: 3406–3415.
48. van der Poll T, van Deventer SJ, Hack CE, Wolbink GJ, Aarden LA, et al. (1992) Effects on leukocytes after injection of tumor necrosis factor into healthy humans. *Blood* 79: 693–698.
49. Richman CM, Johnson GD (1987) Granulocyte/macrophage progenitor cells from peripheral blood and bone marrow differ in their response to prostaglandin E1. *Blood* 70: 1792–1796.
50. Pineda C, Espinosa R, Pena A (2009) Radiographic Imaging in Osteomyelitis: The Role of Plain Radiography, Computed Tomography, Ultrasonography, Magnetic Resonance Imaging, and Scintigraphy. *Semin Plast Surg* 23(2): 80–89.
51. Miller SC, Marks SC (1993) Local stimulation of new bone formation by prostaglandin E1: quantitative histomorphometry and comparison of delivery by minipumps and controlled-release pellets. *Bone* 14(2): 143–151.
52. Lino G, Nishimura K, Omura K, Kasugai S (2008) Effects of Prostaglandin E1 application on rat incisal sockets. *Int J Oral Maxillofac Implants* 23: 835–840.
53. Jee WSS, Ma YF (1997) The in vivo anabolic actions of prostaglandins in bone. *Bone* 21(4): 297–304.
54. Funao H, Ishii K, Nagai S, Sasaki A, Hoshikawa T, et al. (2011) Establishment of a Real-time, Quantitative and Reproducible Mouse Model of Staphylococcal Osteomyelitis using Bioluminescence Imaging. *Infect Immun*: doi:10.1128/IAI.06166-11.
55. Lankinen P, Lehtimäki K, Hakanen AJ, Roivainen A, Aro HT (2012) A comparative 18F-FDG PET/CT imaging of experimental Staphylococcus aureus osteomyelitis and Staphylococcus epidermidis foreign-body-associated infection in the rabbit tibia. *EJNMMI Research* 2: 41.
56. Jee WS, Ueno K, Deng YP, Woodbury DM (1985) The effects of prostaglandin E2 in growing rats: increased metaphyseal hard tissue and cortico-endosteal bone formation. *Calcif Tissue Int* 37: 148–157.
57. Suponitzky I, Weinreb M (1998) Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. *J Endocrinol* 156: 51–57.
58. Miller SC, Pan H, Wang D, Bowman BM, Kopecková P, et al. (2008) Feasibility of Using a Bone-Targeted, Macromolecular Delivery System Coupled with Prostaglandin E1 to Promote Bone Formation in Aged, Estrogen-Deficient Rats. *Pharm Res* 25(12): 2889–2895.
59. Akamine T, Jee WSS, Ke HZ, Li XJ, Lin BY (1992) Prostaglandin E2 prevents bone loss and adds extra bone to immobilized distal femoral metaphysis in female rats. *Bone* 13: 11–22.
60. High WR (1987) Effect of orally administered prostaglandin E2 on conical bone turnover in adult dogs: a histomorphometric study. *Bone* 8: 363–374.
61. Pawar P, Shin PK, Mousa SA, Ross JM, Konstantopoulos K (2004) Fluid Shear Regulates the Kinetics and Receptor Specificity of Staphylococcus aureus Binding to Activated Platelets. *J Immunol* 173: 1258–1265.
62. Jung CJ, Yeh CY, Shun CT, Hsu RB, Cheng HW, et al. (2012) Platelets Enhance Biofilm Formation and Resistance of Endocarditis-Inducing Streptococci on the Injured Heart Valve. *J Infect Dis* 205(7): 1066–1075.